The molecular chaperone heat shock protein 90 (Hsp90) affects the function of many oncogenic signaling proteins including nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) expressed in anaplastic large cell lymphoma (ALCL). While ALK-positive ALCL cells are sensitive to the Hsp90 inhibitor and the geldanamycin (GA) analog, 17-allylamino-17-demethoxygeldanamycin (17-AAG), the proteomic effects of these drugs on ALK-positive ALCL cells are unpublished. In this study, we investigated the cellular, biologic, and proteomic changes occurring in ALK-positive ALCL cells in response to GA treatment. GA induced G 2 /M cell cycle arrest and caspase-3-mediated apoptosis. Furthermore, quantitative proteomic changes analyzed by cleavable isotopecoded affinity tag ™ -LC-MS/MS (cICAT ™ -LC-MS/MS) identified 176 differentially expressed proteins. Out of these, 49 were upregulated 1.5-fold or greater and 70 were downregulated 1.5-fold or greater in GA-treated cells. Analysis of biological functions of differentially expressed proteins revealed diverse changes, including induction of proteins involved in the 26S proteasome as well as downregulation of proteins involved in signal transduction and protein and nucleic acid metabolism. Pathway analysis revealed changes in MAPK, WNT, NF-kB, TGFb, PPAR, and integrin signaling components. Our studies reveal some of the molecular and proteomic consequences of Hsp90 inhibition in ALK-positive ALCL cells and provide novel insights into the mechanisms of its diverse cellular effects.
Introduction
Anaplastic large cell lymphoma (ALCL) is a type of nonHodgkin lymphoma that commonly harbors the t(2;5)(p23;q35) chromosomal aberration, resulting in the expression of the 80 kDa nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) fusion oncoprotein [1] [2] [3] . Native NPM is a nucleolar phosphoprotein, whose functions include ribosomal RNA assembly, chaperone activities, and nuclease activity [4] . ALK is a 200 kDa receptor tyrosine kinase [5] belonging to the insulin receptor superfamily [6] . An N-terminal oligomerization domain within NPM facilitates the dimerization of NPM-ALK, leading to autophos-phorylation and constitutive activation of the ALK tyrosine kinase [5] . Activated ALK induces multiple downstream signaling molecules including phospholipase Cg (PLCg) [7] , phosphatidylinositol-3-kinase (PI3K) [8] /RAC protein kinase (AKT) [9] , Janus kinase 3 (JAK3) [10] , signal transducer and activator of transcription 3 (STAT3) [11] , and the nonreceptor protein kinase sarcoma (SRC) [12] which leads to enhanced cell proliferation, survival, and apoptosis inhibition [13] .
The benzoquinone ansamycins geldanamycin (GA) and derivative, 17-allylamino-17-demethoxygeldanamycin (17-AAG) elicit antitumor activity in a variety of cancer cell lines, including ALCL [14, 15] . Heat shock protein 90 (Hsp90) has been identified as the primary target of GA [16] . Hsp90 is a highly conserved, ubiquitous molecular chaperone that is required for the stability and conformational maturation of a diverse group of client proteins, including components of signaling pathways exploited by cancer cells for survival and proliferation [17] . Hsp90 client proteins include receptor tyrosine kinases such as human epidermal growth factor receptor (EGFR) [18] family kinases, breakpoint cluster region-Abelson (BCR-ABL), and NPM-ALK; cytosolic signaling proteins such as AKT, v-raf-1 murine leukemia viral oncogene homolog 1 (RAF-1), and inhibitor of nuclear factor kappa (IKK) as well as cell cycle regulators including cyclindependent kinase 4 (cdk4), polo-like kinase 1 (PLK1), and survivin [17, 19, 20] . Inhibition of Hsp90 by ansamycins in ALK-positive ALCL cells results in downregulation of NPM-ALK protein kinase activity [14] leading to cellular apoptosis [15] . Clearly, there are multiple cellular targets of Hsp90, yet the comprehensive effects of Hsp90 inhibition in ALK-positive ALCL cells are unknown.
Recent developments in multidimensional LC techniques combined with MS/MS have enabled sensitive and high-throughput detection of low abundance proteins [21] . This technology combined with a cleavable isotope-coded affinity tag (cICAT ™ ) approach allows for the global quantitative analysis of proteins in complex mixtures [22] . In this study, we sought to assess the cellular, biologic, and quantitative proteomic changes occurring in ALK-positive ALCL cells in response to Hsp90 inhibition by GA. Our results demonstrate that GA induced G 2 /M cell cycle arrest and caspase-3-mediated apoptosis. Moreover, we identified 49 proteins that were upregulated 1.5-fold or greater and 70 proteins downregulated 1.5-fold or greater in GA-treated cells. Importantly, we identified several proteins involved in diverse cellular functions, including signal transduction, DNA metabolism, nucleic acid and protein metabolism, cell growth and maintenance, and energy pathways. Some of the downregulated proteins are known to be involved in described signaling pathways such as JAK/STAT as well as pathways previously unreported in ALK-positive ALCL including mitogen-activated protein kinase (MAPK), WNT, nuclear factor kappa B (NF-kB), transforming growth factor b (TGFb), peroxisome proliferator-activated receptor (PPAR), and integrin signaling. Our studies demonstrate some of the molecular mechanisms by which Hsp90 inhibition leads to reduced viability of ALK-positive ALCL cells and reveals cellular proteins whose expression is changed due to GA inhibition of Hsp90.
Materials and methods

Cell culture
The ALK-positive ALCL suspension cell line, SU-DHL-1, was obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany). Cells were cultured in RPMI 1640 (Life Technologies, Grand Island, NY) supplemented with 15% heat-inactivated FBS (Nova-Tech, Grand Island, NE), 25 mM HEPES (Invitrogen, Carlsbad, CA), 2 mM GlutaMAX ™ (Invitrogen), and 1% antibiotic/antimycotic solution (Invitrogen) at 377C in a humidified atmosphere of 95% oxygen and 5% CO 2 .
Cell proliferation assay
Cells were seeded in 6-well plates at a density of 5610 5 cells/ mL in a final volume of 2 mL and subsequently treated with DMSO (vehicle) or concentrations of GA (A.G. Scientific, San Diego, CA) ranging from 0.032 mM through 100 mM in a volume of 10 mL. For each GA concentration, cultures were maintained in triplicate. At the end of 6-, 12-, and 24-h, 1610 4 cells from each control and GA dose were seeded in 96-well plates in triplicate and exposed to 10 mL of WST-1 labeling solution (WST-1 cell proliferation reagent; Roche Diagnostics, Indianapolis, IN) and subsequently returned to the incubator for a period of 2 h. The rate of WST-1 cleavage by mitochondrial dehydrogenases was measured by absorbance at 450 nm using an ELISA plate reader (Molecular Devices, Sunnyvale, CA), with a reference wavelength of 600 nm.
Cell cycle analysis of DNA content
Cells (2 mL; 5610 5 cells/mL in 6-well plates) were treated with 10 mM GA for 24 h, harvested after 6, 12, and 24 h, and prepared for cell cycle analysis as described [23] . Briefly, 1610 5 control and GA-treated cells were fixed in 70% ethanol and stained with 0.1% sodium citrate, 200 mg/mL RNaseA, 0.5% NP-40 and 1 mg/mL propidium iodide (PI) and analyzed using an Epics XL-MCL flow cytometer (Beckman Coulter, Fullerton, CA). Cell cycle phase distribution was determined using EXPO32 ™ software (Beckman Coulter). Three independent experiments were performed in triplicate.
Briefly, 1610 6 control and GA-treated cells were stained with 10 mL annexin V-FITC (Miltenyi Biotechnology, Auburn, CA) and 10 mL PI (Miltenyi Biotechnology) and analyzed on an Epics XL-MCL flow cytometer. Three independent experiments were performed in triplicate.
Caspase-3 activity assay
Cells (2 mL; 5610 5 cells/mL in 6-well plates) were treated with 10 mM GA for 24 h. Caspase-3 protease activity was assessed using the colorimetric Caspase-Glo ™ 3/7 colorimetric assay (Promega, Madison, WI) following the manufacturer's protocol. Briefly, 1610 4 cells were harvested after 6, 12, and 24 h, seeded in 96-well white-walled plates, and incubated with 100 mL of caspase-3 substrate, Ac-DEVDaminoluciferin. After ambient incubation in the dark for 1 h, the release of aminoluciferin was measured on a luminometer (ThermoLabsystems, Waltham, MA). Readings for blank control was subtracted from experimental readings. Furthermore, cells were treated with 100 mM caspase-3 inhibitor, Z-DEVD-FMK (EMD Biosciences, San Diego) for 15 min followed by 10 mM GA and assay repeated. Three independent experiments were performed in triplicate.
Protein isolation and immunoprecipitation
Briefly, cells were collected by centrifugation and washed twice in PBS. Whole cell lysates were prepared using 500 mL RIPA lysis buffer (1% NP-40, 0.1% SDS, 0.5% DOC, 20 mM Tris (pH 7.5), 100 mM NaCl, 0.2% protease inhibitor, and 2 mM activated sodium orthovanadate). After 30-min incubation on ice, samples were centrifuged at 14 000 rpm for 15 min at 47C. Supernatants were recovered and protein concentrations determined using the Bradford colorimetric assay with BSA standards (Pierce Chemical, Rockford, IL).
Immunoblot analysis
For immunoblot analysis, 25 mg of lysate from control and GA-treated cells were mixed with 10 mL of Laemmli reducing buffer and heated at 957C for 5 min. Samples were subsequently resolved by SDS-PAGE on 4-12% gel and electrophoretically transferred to PVDF membranes. Membranes were blocked for 1 h in blocking solution (5% nonfat milk diluted in TBS (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, and 0.1% Tween-20)). The following antibodies were used for immunoblot analysis: mouse polyclonal antibodies against PARP, p21, and p27; goat polyclonal antibodies against ras GTPase-activating protein 3 (RARS3), paracellin-1 (PCLN1), and stanniocalcin-1 (STCN1); and rabbit polyclonal antibody against actin from Santa Cruz Biotechnology (Santa Cruz, CA); mouse polyclonal antibodies against Hsp90 and NEMO (Becton Dickinson Pharmingen, San Diego); rabbit polyclonal antibodies against phospho-ALK and ALK (Cell Signaling, Beverly, MA); rabbit polyclonal antibody against ubiquitin-specific protease 9 (USP9) (Abgent, San Diego); mouse polyclonal antibodies against tankyrase (TNKS) and osteoprotegerin (OPG) and rabbit polyclonal antibodies against suppressor of cytokine signaling 4 (SOCS4; Acris Antibodies, Hiddenhausen, Germany). Membranes were incubated from 1 h at room temperature to 47C overnight with primary antibodies in TBST containing 3% nonfat dry milk, washed five times with TBST, and probed with HRPlabeled secondary antibody at room temperature for 1 h. After five washes with TBST, immunoreactive bands were visualized by chemiluminescence (Amersham Biosciences, Piscataway, NJ). Densitometry was performed using Image J software (National Institutes of Health (NIH), Bethesda, MD) and values were normalized to actin controls.
cICAT labeling of proteins and 3-D LC-MS/MS
SU-DHL-1 control and cells exposed to 10 mM GA were harvested after 12 h incubation and prepared for analysis of differential protein expression as described in ref. [25] (see Fig. 1 for illustration). Briefly, 400 mg of protein from both samples were reduced with 2.5 mM Tris (2-carboxyethyl) phosphine (Sigma) for 1-h at 377C. Isotope labeling was performed by mixing 1 U of light (control sample) or heavy (GA-treated sample) cleavable cICAT reagent with protein samples, following manufacturer's protocol (Applied Biosystems). Labeled proteins from control and treated samples were mixed and dialyzed against 500 mL of urea buffer (2 M urea, 10 mM Tris, pH 8.5) three times for 1-h each at room temperature using a 3.5 kDa cutoff dialysis cassette (Pierce). The dialyzed protein mixtures were then diluted two-fold with 10 mM Tris, pH 8.5, before digestion with 10 mg of modified trypsin (Promega) overnight at 377C. The peptide mixture was then acidified to pH 3.0 by adding TFA before loading onto the cation exchange column. The 3-D liquid chromatographic separation of peptides was performed by first, strong cation-exchange (SCX) chromatography using a 3.6 mm6 20 cm polysulfoethyl A column (Poly LC, Columbia, MD) at a flow rate of 400 mL/min with 35 fractions collected (800 mL/fraction). A two-step linear buffer gradient was used: 5% buffer B and 95% buffer A to 25% buffer B and 75% buffer A for 50 min followed by 25% buffer B and 75% buffer A to 100% buffer B for 18 min (buffer A: 20 mM KH 2 PO 4 , 25% ACN pH 3.0; buffer B 350 mM KCL in buffer A pH 3.0). Next, 35 fractions collected from the offline SCX chromatography were further washed and purified by avidin affinity chromatography (Applied Biosystems) to enrich for cysteine containing (cICAT-labeled) peptides followed by drying and cleaving of eluted peptides. Finally, a 15 mL aliquot of each sample was analyzed by automated nanoflow RP LC/MS using the LCQ Deca XP IT mass spectrometer (ThermoFinnigan, San Jose, CA). Digested peptides were injected by an autosampler, using an ACN gradient (0-60% B in 120 min; A = 5% ACN with 0.4% acetic acid and 0.005% HFBA) through a RP column (75 mm id fused silica packed in-house with 10 cm of 5 mm C18 particles) to elute the peptides at a flow rate of ,200 nL/min into the mass spectrom- Figure 1 . cICAT strategy to isolate and identify differentially expressed proteins in GA-treated cells relative to control. Cells were in the presence of 1% DMSO (control) or 10 mM GA for 12 h. Total cellular protein was precipitated under reduced conditions. Total protein from control cells was labeled with the light cICAT reagent (black circle) and protein from GA-treated cells labeled with the heavy cICAT reagent (gray circles). Samples were mixed, proteolyzed in trypsin, and subjected to avidin affinity chromatography. Isolated cICAT-labeled peptides were subjected to LC-MS/MS to quantitate and identify differentially expressed proteins.
eter. An electrospray voltage of 1.8 kV was used with the ion transfer tube temperature set to 2007C. Peptide analysis was performed using data-dependent acquisition of one MS scan (600-2000 m/z) followed by MS/MS scans of cICAT peptide pairs triggered by the isotope tag mass difference of 9.0 amu. To obtain better peptide coverage, dynamic exclusion was set to a repeat count of 3, with the exclusion duration of 5 min.
Data analyses
The MS/MS acquired data were searched using the SEQUEST algorithm in Bioworks 3.1 (ThermoFinnigan) against human amino acid sequences in the 9.23.2004 download of the NCBI nr.fasta protein database with 191 136 entries. Protein search parameters included a precursor peptide mass tolerance of 6 0.7 amu and fragment mass tolerance of 6 0.1 amu. To account for the isotope label, static modification of cysteine was set to 227.13 and differential modification of cysteine set as 9.0. The search was constrained to tryptic peptides with one missed enzyme cleavage allowed. The peptide matching criteria of a cross correlation score (X corr ).1.2 for 11 peptides, .2.2 for 12 peptides, and .3.2 for 13 peptides, and a delta correlation score (DC n ).0.100 was used as a threshold of acceptance. cICAT protein quantification was performed using XPRESS ™ software (Thermo) which automatically calculates the relative abundance of light and heavy cICAT-labeled peptide as a ratio of light database containing both forward and reverse amino acid sequences for each protein entry. The total number of proteins identified with reverse sequence entries is then multiplied (26) to compensate for doubling the size of the database. Overall, the predicted false positive rate for protein identification by LC-MS/MS was 7.1%.
Differentially expressed proteins were further analyzed using the Ingenuity ™ Pathways Analysis (Ingenuity, Mountain View, CA) web-based application software tool and Bioinformatics Harvester database. Protein accession numbers and corresponding cICAT expression values were saved into the Ingenuity Systems template.xls file. Files were submitted on-line for analysis and comparison to the Ingenuity gene/protein interaction knowledge base (http://www. ingenuity.com/). The results for the pathways and protein interactions were summarized and interaction network images generated with respect to putative canonical pathways. Individual proteins were submitted to the Bioinformatics Harvester database (http://harvester.embl.de/) and protein functional characteristics analyzed.
Results
GA reduces cell viability
In order to establish the proteome-wide changes induced by GA in ALK-positive ALCL cells, we first sought to assess the effects of GA on cell viability.
Previous studies have demonstrated that ansamycins target Hsp90 and inhibit its function as a molecular chaperone. To determine if GA induced similar effects on ALK-positive ALCL cells, we cultured the NPM-ALK-positive ALCL cell line, SU-DHL-1, with increasing concentrations of GA up to 24 h and measured cell viability using the WST-1 assay. As shown in Fig. 2A , the most effective drug concentration was between 4 and 20 mM, with IC 50 values of 10.9, 13.3, and 13.6 mM at 6, 12, and 24 h, respectively. There was no statistically significant reduction in viability between 20 and 100 mM demonstrating the maximum effects of the drug. We subsequently treated SU-DHL-1, Karpas299, and DEL cells in the presence or absence of 10 mM GA and measured cell viability at 6, 12, and 24 h. Figure 2B illustrates the effects of GA on cell viability in a time-dependent manner. Based on our preliminary dose-dependence results, we selected a concentration of 10 mM for subsequent experiments. Control and GA-treated cells were harvested and fixed after 6, 12, and 24 h incubation. Cellular DNA content was determined by flow cytometric analysis after RNase treatment and PI staining. Time and DNA content are denoted on the x-axis and % cells are denoted on the y-axis. Results are expressed as the mean of three independent experiments, performed in triplicate 6 SDs. (C) GA induces apoptosis. Control and GA-treated cells were harvested after 6, 12, and 24 h and stained with annexin V-FITC/PI. Cellular apoptosis was determined by flow cytometric analysis. Annexin V-FITC staining is denoted on the x-axis. PI staining is denoted on the y-axis. Left panels illustrate the staining patterns of control for each time point. Right panels illustrate the staining patterns of GA-treated cells for the same time points. The percent of cells in each particular quadrant represents the mean of three independent experiments. SDs were within 5% of the mean. (D) GA-induced apoptosis is mediated by caspase-3. Control and GA-treated cells were harvested after 6, 12, and 24 h. Caspase-3 activity was determined by luminescence detection of caspase-3 substrate cleavage. Time is denoted on the x-axis. The increase in caspase-3 luminescence as a percent of Z-DEVD-FMK control is denoted on the y-axis. Results are expressed as the mean values of three independent experiments, performed in triplicate 6 SDs.
GA induces G 2 /M cell cycle arrest
We investigated the effects of GA on cell cycle phase distribution to determine whether cell viability reduction was caused by disruption of cell cycle-related events. Cells cultured in 10 mM GA were harvested at the indicated times, stained with PI, and subjected to cell cycle analysis. The percent of cells in G 1 were unchanged at 6 and 12 h, but were reduced by 10.8% after 24 h, relative to control (Fig. 2C) . A reduction of cells in S-phase was seen at 12 and 24 h by 9.9 and 18%, respectively, compared to control. In contrast, cells in G 2 /M increased by 10.4 and 24.2% after 12 and 24 h, compared to control. These data suggest that the reduction of cell viability is due to a block in the G 2 /M transition.
GA induces caspase-3-mediated apoptosis
To further analyze the effects of GA on cell viability, we performed time-course flow cytometric analysis of annexin V-FITC/PI stained cells. Figure 2D illustrates the time-dependent increase in apoptotic cells in response to GA after 6, 12, and 24 h. The fraction of early and late apoptotic cells (annexin V-positive/PI negative and annexin V-positive/PIpositive) increased by 2.3% at 6 h, 7.7% at 12 h, and 36.5% at 24 h, respectively, relative to control. To evaluate the mechanism of GA-induced apoptosis, we analyzed caspase-3 activity. As shown in Fig. 2E , GA induced a time-dependent increase in caspase-3 activity by 1.3, 2.0, and 10.7% at 6, 12, and 24 h, respectively, relative to control. Furthermore, caspase-3 activity was completely inhibited by the caspase-3 inhibitor Z-DEVD-FMK at all time points. These results demonstrate that GA induces caspase-3-mediated apoptosis.
Effects of GA on NPM-ALK, Hsp90, cell cycle regulatory proteins, and apoptosis regulatory proteins
To examine the underlying mechanisms by which GA arrested cells in G 2 /M and induced caspase-3-mediated apoptosis, we performed immunoblot analysis to determine relative expression of phosphorylated and nonphosphorylated NPM-ALK, Hsp90, p21 CIP1 , p27 KIP1 , and PARP. After 12 h drug treatment, the expression of both nonphosphorylated and phosphorylated NPM-ALK expression was markedly reduced in GA-treated cells (Fig. 3) . In contrast, expression of Hsp90 remained unchanged. While expression of the Cdk2 inhibitor, p21 CIP1 was unchanged, the expression of the Cdk4 inhibitor, p27
KIP1 was induced in GA-treated cells. Moreover, PARP underwent cleavage into its 85 kDa fragment with GA treatment, consistent with apoptosis. The levels of actin remained unchanged.
MS/MS analysis of cICAT-labeled peptides
We sought to survey the proteomic changes induced by GA inhibition of Hsp90 using cICAT-LC-MS/MS. Top protein database search hits from SEQUEST were summarized using BioWorks 3.1 and the relative quantification calculated using XPRESS. Figure 4 displays an example of the MS-full scan and MS/MS scan for the cICAT-labeled peptide sequence corresponding to SOCS4. Examination of the data from 35 individual SCX fractions resulted in a total of 2921 peptides identified, which were matched to 1129 known NCBI database entries and 314 unique proteins. Of the 176 cICAT-labeled peptides, 119 were differentially expressed by 1.5-fold or greater at 12 h. Over-and underexpressed proteins were categorized by biological process (Table 1) . A large number of the differentially expressed proteins were downregulated (59%) in response to GA.
The Bioinformatics Harvester database (http://harvester. embl.de/) was used to perform analysis of protein functional characteristics using the 1.5-fold threshold. Seventy-seven percent of the proteins identified and quantified have known functions, while 23% were assigned to the hypothetical category. Furthermore, 84% of the identified proteins were assigned to nuclear, cytoplasmic, membranous, or extracellular locations while the subcellular locations of the remaining 16% are unknown. Figure 5A illustrates localization of overexpressed proteins and Fig. 5B illustrates localization of underexpressed proteins in GA-treated cells. Analysis of localization demonstrated the majority of proteins exist in the nucleus and cytoplasm (67% of overexpressed and 75% of underexpressed).
Analysis of biological pathways of differentially expressed proteins using the Ingenuity Pathways Analysis tool revealed deregulated proteins involved in a variety of pathways, including integrin, estrogen receptor, MAPK, JAK/ STAT, PPAR, and NF-kB signaling as well as those involved in ubiquitin-mediated proteolysis and cell cycle regulation. Several of the proteins are involved in multiple functions such as the versus heavy [25] .
The false-positive error rate for protein identifications was calculated using the composite target/decoy database method [26] . Acquired MS/MS spectra were searched against Cells were in the presence of 1% DMSO (control) or 10 mM GA for 12 h and total cellular protein precipitated. Samples were cICAT labeled and analyzed by LC-MS/MS. Identified peptides of 1.5-fold over-and underexpressed were searched against the Bioinformatics Harvester database for biological function. Proteins were categorized by biological function (over-or underexpressed) and listed are protein names, description, NCBI GI number, fold change, identified peptides, crosscorrelation score, and charge state. Known Hsp90 clients or interacting proteins are designated **, cICAT labeled cysteines are designated *, and unnamed proteins are designated 1. a protein enzyme USP2, which was identified as being involved in ubiquitin-mediated proteolysis, MAPK signaling, and PPAR signaling. Analysis of proteins further implicated those involved in JAK/STAT (underexpressed: IL26, CBLC, and SOCS4), WNT (overexpressed: WNT10B; underexpressed: DKK2, NEMO, and RAC3), MAPK (overexpressed: IL1R1, MAP4K1, MAPK14, RASA3, and Rap guanine nucleotide exchange factor (RAPGEF6); underexpressed: NEMO and RAC3), NFkB (underexpressed: TNFRSF11B and NEMO), and TGFb (underexpressed: RPS6KB1 and SMAD5) pathways.
Immunoblot validation of differentially expressed proteins
We selected eight differentially expressed proteins identified by cICAT-LC-MS/MS to validate changes in expression by immunoblot. Importantly, relative differences between cICAT and immunoblot were within 50% of each other. Immunoblot analysis demonstrated that USP9, ras GTPaseactivating protein 3 (GAP1), PCLN1, and STCN were overexpressed in GA-treated cells relative to control by 5.6-, 2.8-, 2.6-, and 2.1-fold (cICAT), respectively. Proteins that were underexpressed in GA-treated cells including tankyrase, SOCS4, IKKk (NEMO), and OPG were also confirmed by immunoblot analysis and were reduced by 4.2-, 2.4-, 2.4-, and 1.8-fold (cICAT), respectively, relative to control. Figure 6 illustrates the respective overexpressed proteins (left panels) and underexpressed proteins (right panels) with corresponding cICAT and densitometry ratios.
Discussion
ALK-positive ALCLs are most commonly associated with the t(2;5)(p23;q35) chromosomal aberration, resulting in expression of the chimeric NPM-ALK oncoprotein [1] [2] [3] . Survival of ALK-positive ALCL cells is mediated by the activation of signaling pathways [7] [8] [9] [10] [11] [12] that inhibit apoptosis and promote cell proliferation [13] . Vital to the survival of these cells is the function of the chaperone protein Hsp90, which enhances the stability of the NPM-ALK protein [14, 15] . (1:1000), anti-GAP1 (1:300), anti-PCLN (1:300), anti-STCN (1:300), anti-tankyrase (1:1000), anti-SOCS-4 (1:1000), anti-NEMO (1:1000), anti-OPG (1:500), and anti-actin (1:500). Immunoblots were then incubated at room temperature for 1 h followed by probing with respective HRP-conjugated secondary antibodies and visualized by chemiluminescence. The left panels depict the overexpressed proteins as identified by LC-MS/MS in control and cells exposed to 10 mM GA. The right panels depict the underexpressed proteins as identified in the same samples. Both cICAT-and densitometry fold-change is listed below the 10 mM GA lanes. Actin served as a loading control.
Hsp90 assists in the functional maturation of a diverse group of proteins, particularly those involved in cancer-related signaling [16] . GA binds to the N-terminus ATP-binding domain of Hsp90, thereby preventing Hsp90 from performing its chaperone duties [27] . Inhibition of Hsp90 by ansamycins reduces the expression levels of its client proteins by subjecting them to ubiquitin-mediated proteasomal degradation [14, 28] . GA and its analog, 17-AAG, have been shown to reduce the expression of NPM-ALK and result in subsequent cellular apoptosis [14, 15] . However, the comprehensive proteomic changes induced by the drug are currently unknown. The results of our quantitative proteomic study demonstrate that the effects of GA on ALK-positive ALCL cells are diverse and affect proteins involved in cell signaling, DNA metabolism, protein metabolism, cell growth, and transport.
In this study, we demonstrate that the NPM-ALK-positive ALCL cell line, SU-DHL-1, is sensitive to GA inhibition of Hsp90. The display of both increased caspase-3 activity (Fig. 2D ) and cleavage of PARP (Fig. 3) indicate that Hsp90 inhibition by GA induces the mitochondria-mediated apoptotic pathway, in line with other studies using GA in a variety of cell lines [29] [30] [31] [32] . Furthermore, GA treatment resulted in the downregulation of both the native NPM-ALK and phospho-NPM-ALK (Fig. 3 ), in agreement with previous studies using 17-AAG in ALK-positive ALCL cells [14, 15] . These results reinforce the critical role of NPM-ALK in the survival of these cells [14, 15] . We further showed that the expression of Hsp90 itself did not change in response to GA treatment (Fig. 3) , suggesting that GA does not inhibit expression of Hsp90 [33] .
Cell cycle analysis revealed that GA induced G 2 /M cell cycle arrest (Fig. 2B) . While this observation contradicts other studies that report G 1 arrest in cells exposed to 17-AAG [14, 15] , GA has been shown to induce G 2 /M arrest in erythroleukemic cells through inhibition of Cdc2 and induction of p27
Kip1 [34] and other G 2 /M regulators [17] . The induction of p27
Kip1 but not p21 Cip1 (Fig. 3 ) observed in our studies is consistent with G 2 /M cell cycle arrest.
Analysis of the proteome of GA-treated cells demonstrated that numerous proteins that perform diverse cellular functions are affected by Hsp90 inhibition (Table 1) . Proteins known to be involved in signaling pathways important for survival of ALK-positive ALCL cells include PI3K/AKT [8, 9] , JAK/STAT [10, 11] , and PLCg [7] . Our quantitative proteomic analysis revealed differential expression of proteins belonging to multiple signaling pathways including those in the MAPK (overexpressed: MAP4K1, RASA3, RAPGEF6, MAPK14, and IL1R1; underexpressed: NEMO and RAC3), JAK/STAT (underexpressed: IL26, CBLC, and SOCS4), WNT (overexpressed: WNT10B; underexpressed: RAC3, NEMO, and DKK2), NF-kB (overexpressed: IL1R1; underexpressed: NEMO and TNFRSF11B), and TGFb (underexpressed: RPS6KB1 and SMAD5) pathways. Because of the roles of these pathways in survival signaling, we were surprised to identify 41% overexpressed proteins. However, because samples were analyzed after 12 h drug exposure, these results may be indicative of secondary and tertiary effects of the drug on MAPK signaling. For example, MAP4K1 has been reported to influence FAS-mediated apoptosis and caspase-3-mediated cleavage of MAP4K1 at Asp385 converting MAP4K1 from an activator of the transcription factor NF-kB into an NF-kB inhibitor, thus favoring apoptosis [35, 36] .
The role of Hsp90 as a molecular chaperone involved in the folding of protein kinases has been well described [18, 37, 38] . Our study also showed that GA treatment resulted in decreased expression of many protein kinases (PTK2B, RPS6KB1, and MAK), including serine/threonine kinases (RPS6KB1 and MAK), and tyrosine kinase (PTK2B) and NPM-ALK. Whether these protein kinases are downstream targets of NPM-ALK and/or client proteins of Hsp90 remains to be determined.
Several Hsp90 client proteins and interactors were found to be differentially expressed by quantitative proteomics and validated by immunoblot analysis, including NPM-ALK, STIP1 [39] , NEMO [40] , MAK [41] , and MCPH1 [42] . Importantly, all of the identified Hsp90 clients and interactors were underexpressed in response to GA, which provides further validation of our results. Moreover, these data suggest that many of the diverse proteins whose expression changed in response to GA may be due to the reduced expression of Hsp90 clients and interactors other than, or in addition to, NPM-ALK. For example, STIP1 has been shown to mediate the association of the Hsp70-client protein complex with Hsp90 [39] . Moreover, the reduced expression of STIP1 may be indicative of incapacitated Hsp90, and could serve as a surrogate marker of disease states in which Hsp90 is overexpressed.
GA inhibits signal transduction by inducing ubiquitination and proteasomal degradation of proteins chaperoned by Hsp90 [16, 20, 43] . Proteins associated with ubiquitin-mediated proteasomal degradation machinery were differentially expressed (overexpressed: PDC, CBLC, PSMD9, USP9X, and PSMD7; underexpressed: PSMD2, CAPN5, and VCIP135). Interestingly, two of the overexpressed proteins (PSMD9 and PSMD7) are non-ATPase members of the 26S proteasome. PDC functions in preventing proteins from being degraded and associates with a subunit of the 26S proteasome/19S regulatory complex [44, 45] suggesting that Hsp90 may regulate the expression of components of the proteasome.
In summary, our studies illustrate the diverse proteins whose expression is changed due to GA inhibition of Hsp90. Importantly, we identified proteins of both known and previously unreported signaling pathways downregulated in response to GA-treatment. We also identified downregulated Hsp90 client proteins and direct interactors as well as upregulation of proteins involved in the 26S proteasome. Our studies illustrate the utility of a proteomics-based approach in the identification and relative quantification of proteins and signaling pathways involved in cancer pathogenesis and the potential for exploitation of new knowledge thereby obtained in approaches to the specifically targeting deranged signaling pathways. 
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